By VETTAPHARMA reporter – Derek Roche: AstraZeneca reported new progress for baxdrostat, its investigational aldosterone synthase inhibitor, highlighting continued advancement in treatment-resistant and hard-to-control hypertension.
Baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in the BaxHTN and Bax24 Phase III trials, supporting its development as a potential first-in-class therapy targeting aldosterone-driven hypertension.
In the Bax24 Phase III trial, baxdrostat achieved a 14 mmHg placebo-adjusted reduction in 24-hour ambulatory systolic blood pressure at 12 weeks in patients with resistant hypertension, with blood pressure control maintained throughout the day and night.
The programme also includes the ongoing Prevent-HF Phase III trial, evaluating baxdrostat in combination with dapagliflozin in patients with chronic kidney disease and hypertension, reflecting AstraZeneca’s strategy of expanding the molecule across cardiovascular and renal indications.
Hypertension affects approximately 1.4 billion people worldwide, with nearly 50% of patients on multiple therapies remaining uncontrolled, highlighting the significant unmet need for new treatment approaches targeting hormonal drivers of disease.
The development of baxdrostat aligns with AstraZeneca’s strategy of strengthening its cardiovascular, renal and metabolism (CVRM) portfolio through innovative therapies addressing underlying disease mechanisms rather than symptom management alone.
For patients with resistant hypertension, baxdrostat may offer a potential new treatment option capable of delivering sustained round-the-clock blood pressure control, which could help reduce long-term cardiovascular and renal risks associated with uncontrolled hypertension.
From a commercial perspective, baxdrostat represents a significant future growth opportunity for AstraZeneca, with analysts and company projections indicating potential peak annual sales exceeding $5 billion if approved across multiple cardiovascular and renal indications.
